Neurizon Therapeutics (FRA:ECQ0) ROCE % : -77.74% (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Neurizon Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Neurizon Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2023 was -77.74%.

Neurizon Therapeutics ROCE % Historical Data

The historical data trend for Neurizon Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurizon Therapeutics ROCE % Chart

Neurizon Therapeutics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

ROCE %

Get a 7-Day Free Trial

-14.30

-12.96

-17.52

-85.44

-88.60

Neurizon Therapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial															-9.74	0.45	-179.25	-77.74	-96.79

Neurizon Therapeutics ROCE % Calculation

Neurizon Therapeutics's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	-3.797	/	( ( (6.7 - 0.775)	+	(3.797 - 0.834) )	/ 2 )
	=	-3.797	/	( (5.925	+	2.963)	/ 2 )
	=	-3.797	/	4.444
	=	-85.44 %

Neurizon Therapeutics's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-2.932	/	( ( (3.797 - 0.834)	+	(5.333 - 0.753) )	/ 2 )
	=	-2.932	/	( ( 2.963	+	4.58 )	/ 2 )
	=	-2.932	/	3.7715
	=	-77.74 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Neurizon Therapeutics (FRA:ECQ0) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Neurizon Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Neurizon Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurizon Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurizon Therapeutics Ltd (FRA:ECQ0) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ECQ0:Germany NUZ:Australia

Address

96-100 Albert Road, Level 4, South Melbourne, Melbourne, VIC, AUS, 3205

Website

https://www.neurizon.com

Neurizon Therapeutics Ltd is a clinical-stage biotech company that develops drug discovery intellectual property for the treatment of different types of neurodegenerative diseases. Its product pipeline is NUZ-001 (S-Monepantel).

Neurizon Therapeutics Headlines

No Headlines